Cardiovascular Applications of Stem Cells (eBook)

The book covers multifarious aspects of stem cell-based therapy for cardiovascular diseases. In addition to stem cells from different sources for cell-based therapy, it covers stem cell organoids and stem cell-derived exosomes in regenerative medicine. The book also encompasses advances in state-of-the-art infrastructure to improve the maturation aspects of pluripotent stem cells-derived cardiomyocytes using a novel scaffold-based cell culture system for cell delivery in experimental animal models and clinical settings. Besides the use of mesenchymal stem cells, the book includes chapters on the use of cardiac progenitor cells (CPCs), microtissue implantation, use of PSCs for valvulopathies, application of de-cellularized organ arrays as natural scaffolds for cardiac tissue engineering, use of epicardial stem cells, and skeletal myoblasts in cell-based therapy for myocardial regeneration. Besides the cell-based therapy approach, the book also reviews the stem cell-derived exosomes, their characteristics, and engineering strategies to enhance their therapeutic potential via targeting and drug loading and use in disease models. Additionally, the book also discusses the latest research on injectable hydrogels for cardiovascular regeneration and how hydrogel-based delivery protects the cells and their retention post-engraftment in the heart, a problem, which significantly reduces the efficacy of cell-based therapy.

Dr. Khawaja Husnain Haider is currently a Professor of Cellular and Molecular Pharmacology (Stem cells and Gene Therapy) and Chairman of the Basic Sciences Department (Medical Program) at Sulaiman AlRajhi University. Before his current assignment, he served in several prestigious institutions in various parts of the world. He has also served as Principal Investigator (PI) and Co-PI on multiple National Institute of Health (NIH) funded stem cell research projects. He has been on the editorial boards of various research journals and an invited reviewer for several respected international journals. His research focuses on using DNA, miRNAs, and stem cells as 'drugs,' a topic that has gained popularity in regenerative medicine. He has published nearly 325 book chapters, abstracts, and research papers in various books and leading research journals, including Circulation, Circulation Research, Cardiovascular Research, JCMM, the Journal of Biological Chemistry, Cell Cycle, Basic Research in Cardiology, and Antioxidant Redox Signaling. He has also given numerous presentations and edited seven books covering various facets of stem cells and their applications from drug to drug development.

---

The book covers multifarious aspects of stem cell-based therapy for cardiovascular diseases. In addition to stem cells from different sources for cell-based therapy, it covers stem cell organoids and stem cell-derived exosomes in regenerative medicine. The book also encompasses advances in state-of-the-art infrastructure to improve the maturation aspects of pluripotent stem cells-derived cardiomyocytes using a novel scaffold-based cell culture system for cell delivery in experimental animal models and clinical settings. Besides the use of mesenchymal stem cells, the book includes chapters on the use of cardiac progenitor cells (CPCs), microtissue implantation, use of PSCs for valvulopathies, application of de-cellularized organ arrays as natural scaffolds for cardiac tissue engineering, use of epicardial stem cells, and skeletal myoblasts in cell-based therapy for myocardial regeneration. Besides the cell-based therapy approach, the book also reviews the stem cell-derived exosomes,their characteristics, and engineering strategies to enhance their therapeutic potential via targeting and drug loading and use in disease models. Additionally, the book also discusses the latest research on injectable hydrogels for cardiovascular regeneration and how hydrogel-based delivery protects the cells and their retention post-engraftment in the heart, a problem, which significantly reduces the efficacy of cell-based therapy.